Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 4, 2011, Pages 765-768

  Radeski, Dejan ^a   Cull, Gavin M ^a   Cain, Michael ^a   Hackett, L Peter ^b   Ilett, Kenneth F ^b,c  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Ara C; Ara U; Cytarabine; Dialysis; Pharmacokinetics; Renal failure

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; HEMODIALYSIS FLUID; PREDNISOLONE; RITUXIMAB; URACIL ARABINOSIDE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD SAMPLING; CANCER RELAPSE; CASE REPORT; CONTINUOUS INFUSION; DIALYSATE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; PRIORITY JOURNAL; STEADY STATE;

ANTIMETABOLITES, ANTINEOPLASTIC; ARABINOFURANOSYLURACIL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTARABINE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; NEUROTOXICITY SYNDROMES; RENAL DIALYSIS;

EID: 79954448014     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1373-2     Document Type: Article

References (14)

1. LH Lindner H Ostermann W Hiddemann, et al. 2008 AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity Int J Hematol 88 381 386 18836794 10.1007/s12185-008-0171-7 1:CAS:528:DC%2BD1MXhsFGmu7g%3D
2. LE Damon W Plunkett CA Linker 1991 Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D- arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine Cancer Res 51 4141 4145 1868435 1:STN:280:DyaK3MzjtVWiuw%3D%3D
3. EH Rubin JW Andersen DT Berg CA Schiffer RJ Mayer RM Stone 1992 Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia J Clin Oncol 10 948 953 1588374 1:STN:280:DyaK383mvV2msg%3D%3D
4. GA Smith LE Damon HS Rugo CA Ries CA Linker 1997 High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency J Clin Oncol 15 833 839 9053511 1:CAS:528:DyaK2sXhsVamsLc%3D (Pubitemid 27075136)
5. JM Poschl G Klaus U Querfeld R Ludwig O Mehls 1993 Chemotherapy with cytosine arabinoside in a child with Burkitt's lymphoma on maintenance hemodialysis and hemofiltration Ann Hematol 67 37 39 8334197 10.1007/BF01709664 1:STN:280:DyaK3szis1Kktw%3D%3D (Pubitemid 23231384)
6. JR Wermeling JM Pruemer FM Hassan A Warner AJ Pesce 1989 Liquid-chromatographic monitoring of cytosine arabinoside and its metabolite, uracil arabinoside, in serum Clin Chem 35 1011 1015 2731341 1:CAS:528: DyaL1MXksV2ku7Y%3D (Pubitemid 19161275)
7. M Burk M Volmer K Fartash W Schneider 1995 Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma Arzneimittelforschung 45 616 619 7612064 1:CAS:528:DyaK2MXmsVCqtrc%3D
8. Heinzel G, Tanswell P (1993) Compartmental analysis methods manual, In: Heinzel G, Woloszcak R, Thomann P (eds) Topfit 2.0 Pharmacokinetic and pharmacodynamic data analysis system for the PC Stuttgart. Gustav Fischer, Stuttgart, pp 5-140
9. W Kern E Schleyer M Unterhalt B Wormann T Buchner W Hiddemann 1997 High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study Cancer 79 59 68 8988727 10.1002/(SICI)1097-0142(19970101)79: 1<59::AID-CNCR9>3.0.CO;2-H 1:CAS:528:DyaK2sXmtVGiug%3D%3D (Pubitemid 26425508)
10. A Isla AR Gascon J Maynar A Arzuaga D Toral JL Pedraz 2005 Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients Clin Ther 27 599 608 15978309 10.1016/j.clinthera.2005.05.004 1:CAS:528:DC%2BD2MXht1WmtL3N (Pubitemid 40835971)
11. DM Lanese PS Alfrey BA Molitoris 1989 Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers Kidney Int 35 1409 1412 2770120 10.1038/ki.1989.141 1:STN:280:DyaL1MzmtlWmsg%3D%3D (Pubitemid 19167935)
12. E Jabbour S O'Brien H Kantarjian, et al. 2007 Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia Blood 109 3214 3218 17209054 10.1182/blood-2006-08-043646 1:CAS:528:DC%2BD2sXksFWitbw%3D (Pubitemid 46572506)
13. I Hilgendorf D Wolff C Junghanss, et al. 2008 Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation Ann Hematol 87 1009 1012 18704421 10.1007/s00277-008-0546-0 1:CAS:528:DC%2BD1cXht1OisLjI
14. S Phuphanic B Maria R Braeckman M Chamberlain 2007 A pharmacokinetic study of intra-CSF administered encapsulated cytrarabine (DepoCyt ®) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study J Neurooncol 81 201 208 10.1007/s11060-006-9218-x (Pubitemid 44963980)